IMU 4.00% 4.8¢ imugene limited

Ann: IMUGENE ANNOUNCES PUBLICATION OF ASCO 2022 PD1-VAXX ABSTRACT, page-46

  1. 333 Posts.
    lightbulb Created with Sketch. 144
    Freedom and Steini,

    Correct me if I'm wrong, but IMU's Phase 1 trial with CheckVacc targeting TNBC is as a monotherapy only. No combo with Keytruda at this stage. So still a long way off before the dollars come flooding in.

    However, am looking forward to Phase 1b trial with Roche when we combine with Tecentriq targeting NSCLC. I think we can expect to see a big improvement in CR and SD.
 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.